State-run hydro power generation company NHPC would invest around Rs 15,000 crore for developing two projects in the neighbouring country Myanmar. NHPC is preparing detailed project report (DPR) for 1,200 MW Htamanthi and 660 MW Shwezaye Hydro Power Projects on Chindwin River in Myanmar. The cost incurred for producing one megawatt of hydro power is approximately Rs 8 crore. Currently, NHPC has 14 operational power stations with a total installed capacity of 5,295 MW. NHPC has commissioned the 14.1 MW Devighat Project in Nepal and 60 MW Kurichu Project in Bhutan on turnkey basis. The company is providing its technical expertise in the area of hydro power development in countries like Myanmar, Bhutan and Tajikistan. The company is also preparing DPRs for the 670 MW Chamkarchhu-I and 1,800 MW Kuri-Gongri HE projects in Bhutan.
City based-drug maker Aurobindo Pharma is eyeing overseas and domestic acquisitions to achieve a $2 billion turnover by 2014. The company may lose $40 million in revenues due to the ongoing import ban issued by the US Food and Drug Administration on production from the company’s Unit-VI facility. The company board recently appointed a restructuring committee to examine if the company needs to be restructured and its businesses spun off or demerged into separate formulations and bulk actives companies. Another proposal under consideration by the company is to acquire a city-based branded formulations marketing company.
GVK Power & Infrastructure has emerged as the frontrunner to develop and operate the 330 km stretch Shivpuri-Dewas national highway in Madhya Pradesh. The Rs 2,815 crore project had received responses from 14 bidders on opening of the bids. The bidders included Indian construction majors like Reliance Infrastructure, Gammon Infrastructure, L&T Infrastructure Development Infrastructure amongst others. GVK emerged as the best bidder by offering an annual premium of Rs 180.9 crore to NHAI. The premium will increase by 5 percent every year during the concession period of 30 years.
Orchid Chemicals and Pharmaceuticals is planning to enter into manufacturing of formulation drugs in three new therapeutic segments in the current fiscal. The company would invest around Rs 200 crore to support the new business. The proposed investment is to support the company’s foray into therapeutic segments in which manufacturing process is difficult and has less competition. The current fiscal’s investment of Rs 200 crore will be on setting up of a facility to manufacture the new products.
Electrical equipment maker Jyoti entered into collaboration agreement with DMW Corporation for manufacturing pumps for large power and irrigation projects in India. The company announced the collaboration yesterday. The collaboration marks company’s entry into larger business segment. Jyoti is anticipating its business to grow by Rs 200-300 crore in next five years. Recently, Jyoti invested close to Rs 100 crore in capacity and expansion, which will be utilised to manufacture pumps for large power and irrigation projects in India. DMW Corporation is a 101-year-old Japanese company, engaged in manufacturing pumps for nuclear and thermal power projects and large irrigation projects.
Drugmaker JB Chemicals & Pharmaceuticals is in talks with South African drug makers for new long-term contract manufacturing opportunities. The mid-sized company agreed in May to sell its over-the-counter business in Russia to an affiliate of US-based Johnson & Johnson for $260 million. The company is now fully focused on formulations and contract manufacturing business to drive growth.
ABB has won orders worth Rs 16.1 crore to supply turnkey power and automation solutions for three photovoltaic (PV) solar power plants with a combined capacity of 11 megawatts (MW) in India. The order comprises of two 5-MW PV solar power plants and one 1-MW PV solar power plant, which on completion in October this year, will have an annual generating capacity of 17.6 gigawatt-hours of electricity. This will save CO2 emissions of 12,500 MTs per year, equivalent to the emissions of 3,100 cars annually.
Tata Motors reported total sales during July, 2011, to 63,761 units from 67,800 units in the same month of 2010 recording a decline of 5.96%. The firm’s total passenger vehicles sales in the domestic market stood at 17,192 units in July, a fall of 38.30% from 27,865 units in the same month last year. Tata Nano’s sales stood at 3,260 units during the month, down 64%. The ‘Indica’ range reported sales of 5,860 units, down 32% against July, 2010. The ‘Indigo’ family recorded sales of 4,877 units, a decrease of 30% in comparison to the same month last year while sales of ‘Sumo’, ‘Safari’ and ‘Aria’ fell by 2% to 3,195 units. In the commercial vehicles segment, the company sold 40,798 units in the domestic market during the month under review, compared to 35,694 units in the same month last year, translating into an increase of 14.30%.
Fortis Healthcare (India) is likely to start six new hospitals in southern and western India that could entail an investment of up to Rs 1,050 crore. The expansion will increase the network’s bed capacity by 1,400 beds to 9,700. The hospitals will be set up in Bangalore, Chennai, Pune, Hyderabad, Indore and Jabalpur. With the upper limit of Rs 75 lakh per bed, the new 1,400 beds would need an investment of Rs 1,050 crore. The tertiary care hospital at Pune and super speciality hospital in Chennai would commence operations in 2012, while the hospital projects at Hyderabad and Indore are in an advanced stage of planning.
As many as 20 companies have shown interest in setting up the 4000 MW Ultra Mega Power project (UMPP) at Bedabahal in Orissa. The companies include JSW Energy,NTPC, Nalco, Tata Power, Welspun Energy, AES India, Torrent Power, L&T, Adani Power and GVK Energy Ventures. Lanco Hydro Power Ventures, GMR Energy, Senator Energy, Jaiprakash Power Ventures, Gujarat Paguthan Energy Corporation, CESC, Jindal Power, Sterlite Energy, Vadinar Power Company and Aditya Birla Power Venture havealso shown interest in the project.